ARGX vs ARQT
argenx SE vs Arcutis Biotherapeutics, Inc. — AI-powered side-by-side comparison
VS
ARQT
Arcutis Biotherapeutics, Inc.
64
Buy
| Metric | ARGX | ARQT |
|---|
| AI Score |
69
|
64
|
| Price |
$864.40
|
$26.21
|
| P/E Ratio |
31.34×
|
118.80×
|
| ROE |
17.6%
|
-8.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.9%
|
91.1%
|
| Debt / Equity |
0.01×
|
0.52×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
47.9
|
44.7
|
| Beta |
-0.022
|
1.526
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ARGX versus ARQT.
ARGX leads by 5 points.
ARGX scores 69/100 (Buy) versus ARQT at 64/100 (Buy).
ARGX Committee View
67% agreement
6 analysts
The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
ARQT Committee View
60% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 15.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 76.1% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- P/E of 114.1 is expensive by classic value standards — Value
- Price-to-book of 18.8x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical